Lingdolinurad - Atom Therapeutics
Alternative Names: ABP-671Latest Information Update: 05 Nov 2025
At a glance
- Originator Atom Bioscience
- Developer Atom Therapeutics
- Class 2 ring heterocyclic compounds; Alkanes; Antigouts; Antirheumatics; Bromobenzenes; Imidazoles; Ketones; Nitriles; Phenols; Pyridines; Small molecules; Uricosurics; Urologics
- Mechanism of Action SLC22A12 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Gout
- Phase II Hyperuricaemia
- Phase I Renal failure
Most Recent Events
- 05 Nov 2025 CAS number added (https://pubchem.ncbi.nlm.nih.gov/compound/Lingdolinurad#section=SMILES)
- 05 Nov 2025 Chemical name/molecular formula added (https://pubchem.ncbi.nlm.nih.gov/compound/Lingdolinurad#section=SMILES)
- 05 Nov 2025 Chemical structure information added.